Product data sheet

MedKoo Cat#: 414430 Name: Naloxegol Free Base CAS: 854601-70-0 (free base) Chemical Formula: $C_{34}H_{53}NO_{11}$ Exact Mass: 651.3619 Molecular Weight: 651.794	
Product supplied as:	Powder
Purity (by HPLC):	≥ 98%
Shipping conditions	Ambient temperature
Storage conditions:	Powder: -20°C 3 years; 4°C 2 years.
	In solvent: -80°C 3 months; -20°C 2 weeks.

1. Product description:
Naloxegol Free Base is a peripherally acting opioid receptor antagonist specific for mu-opioid receptors. Used to decrease the constipating effects of opioids.

2. CoA, QC data, SDS, and handling instruction
SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under "QC And Documents" section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed.

3. Solubility data

Solvent	Max Conc. mg/mL	Max Conc. mM
TBD	TBD	TBD

4. Stock solution preparation table:

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.53 mL	7.67 mL	15.34 mL
5 mM	0.31 mL	1.53 mL	3.07 mL
10 mM	0.15 mL	0.77 mL	1.53 mL
50 mM	0.03 mL	0.15 mL	0.31 mL

5. Molarity Calculator, Reconstitution Calculator, Dilution Calculator
Please refer the product web page under section of "Calculator"

6. Recommended literature which reported protocols for in vitro and in vivo study
In vitro study

Floettmann E, Bui K, Sostek M, Payza K, Eldon M. Pharmacologic Profile of Naloxegol, a Peripherally Acting μ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation. J Pharmacol Exp Ther. 2017 May;361(2):280-291. doi: 10.1124/jpet.116.239061. Epub 2017 Mar 23. PMID: 28336575; PMCID: PMC5399635.

In vivo study

TBD

7. Bioactivity
Biological target:

Naloxegol Free Base is a peripherally acting opioid receptor antagonist specific for mu-opioid receptors.

In vitro activity

At the human μ-opioid receptor in vitro, naloxegol was a potent inhibitor of binding (Ki = 7.42 nM) and a neutral competitive antagonist (pA_2 - 7.95); agonist effects were <10% up to 30 μM and identical to those of naloxone.

Reference: J Pharmacol Exp Ther. 2017 May;361(2):280-291. https://pubmed.ncbi.nlm.nih.gov/28336575/

Product data sheet

In vivo activity

TBD

Note: The information listed here was extracted from literature. MedKoo has not independently retested and confirmed the accuracy of these methods. Customer should use it just for a reference only.